Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Ascelia's Q1 report and recent development in the company.</li><li>We see two clear triggers ahead: The PDUFA-date on the 3rd of July and a potential licensing agreement.</li></ul>

Redeye comments on Ascelia's Q1 report and recent development in the company.We see two clear triggers ahead: The PDUFA-date on the 3rd of July and a potential licensing agreement.

Ascelia Pharma (Q1 review): PDUFA-date closing in

<ul><li>Redeye gives a short comment on the directed issue in Ascelia.</li></ul>

Redeye gives a short comment on the directed issue in Ascelia.

Ascelia: Directed issue ahead of PDUFA-date

<ul><li>Redeye returns with an update following Ascelia Pharma's Q4 update, which contained no material surprises.</li><li>We largely reiterate our view and see 2026 as a transformative year for the company.</li></ul>

Redeye returns with an update following Ascelia Pharma's Q4 update, which contained no material surprises.We largely reiterate our view and see 2026 as a transformative year for the company.

Ascelia Pharma (Q4 review): On the path to approval

<ul><li>Redeye gives a short comment on the news that the FDA has accepted Ascelia’s NDA application for Orviglance for review.</li></ul>

Redeye gives a short comment on the news that the FDA has accepted Ascelia’s NDA application for Orviglance for review.

Ascelia: FDA accepts Orviglance NDA for review

<ul><li>Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises.</li><li>We make some near term changes to our estimates but largely reiterate our view.</li></ul>

Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises.We make some near term changes to our estimates but largely reiterate our view.

Ascelia Pharma (Q3 review): Partnering in focus ahead

Sweden

Ascelia Pharma AB operates as a drug development company. The Company develops medicines and drugs for the treatment of liver metastases and gastric cancer. Ascelia Pharma serves patients in Sweden.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ascelia Pharma (ACE SS)

Ascelia Pharma (Q1 review): PDUFA-date closing in

Redeye comments on Ascelia's Q1 report and recent development in the company. We see two clear triggers ahead: The PDUFA-date on the 3rd of July...

Redeye

Ascelia: Directed issue ahead of PDUFA-date

Redeye gives a short comment on the directed issue in Ascelia.

Redeye

Ascelia Pharma (Q4 review): On the path to approval

Redeye returns with an update following Ascelia Pharma's Q4 update, which contained no material surprises. We largely reiterate our view and see...

Redeye

Ascelia: FDA accepts Orviglance NDA for review

Redeye gives a short comment on the news that the FDA has accepted Ascelia’s NDA application for Orviglance for review.

Redeye

Ascelia Pharma (Q3 review): Partnering in focus ahead

Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises. We make some near term changes to our estimates...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)